Company news

Validation of IgG, IgM multiplex plasmonic gold platform in French clinical cohorts for the serodiagnosis and follow-up of Toxoplasma gondii infection

Diagnostic Microbiology & Infectious Disease, March 2017 Volume 87, Issue 3, Pages 213–218

Christelle Pomares, Bo Zhang, Shylaja Arulkumar, Geraldine Gonfrier, Pierre Marty, Su Zhao, Steven Cheng, Meijie Tang, Hongjie Dai, Jose G. Montoya

Abstract

We report the use of the multiplexed T. gondii IgG, IgM test on plasmonic gold (pGOLD) platform in the setting of T. gondii infection by analyzing 244 sera from Nice, France (seroconversion, chronically infected, non-infected and newborns serum samples). Results were compared with commercial tests for the detection of IgG and IgM and their overall clinical final interpretation of a complete serological profile. The IgG and IgM test results on the platform were in agreement in, respectively, 95% and 93% with the commercial kits. When comparing with the overall clinical interpretation of the serological profile, the agreement reached 99.5% and 97.7% for IgG and IgM, respectively. This innovative pGOLD platform allows detection of both IgG and IgM simultaneously with only ~1 microliter of serum. The multiplexed IgG/IgM test on pGOLD platform is a strong candidate for its use in the massive screening programs for toxoplasmosis during pregnancy.

Read more at Diagnostic Microbiology & Infectious Disease